Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lyophilized Microbiota
- Development stage
- Unknown
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lyophilized Microbiota is an investigational live biotherapeutic product developed by The University of Texas Health Science Center at Houston (UTHealth Houston) for the treatment of recurrent *Clostridioides difficile* infection (CDI). The therapy consists of a complex community of intestinal bacteria derived from screened healthy donors, which is filtered and freeze-dried (lyophilized) to create a stable, encapsulated inoculum. Administered orally, the product is designed to restore microbial diversity and functional balance within the gut microbiome. By re-establishing colonization resistance, the transplanted microbiota outcompetes *C. difficile* pathogens and restores normal bile acid metabolism, thereby preventing further recurrences of the infection. It has been evaluated in Phase 1/2 clinical trials comparing its safety and efficacy to frozen microbiota delivered via retention enema.
- Other names
- Lyophilized donor intestinal bacteriaLyophilized fecal microbiota transplantationLyophilized FMTLyophilized Microbiota
Beyond the preview
Go deeper on Lyophilized Microbiota.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lyophilized Microbiota.